<scp>HBV</scp> deferrals and <scp>NAT</scp> window period: Assessing the impact of 3‐month versus 4‐month testing delays
Adopting an HBV deferral of 3 months poses a negligible incremental risk compared with 4 months and is acceptable given the resulting gain in newly eligible donors.
Authors
- Katy Davison (ORCID: https://orcid.org/0000-0002-6337-892X)
- Christian Renaud (ORCID: https://orcid.org/0000-0001-5685-5380)
- Sheila F. O’Brien (ORCID: https://orcid.org/0000-0002-5332-2789)
- Marc Germain (ORCID: https://orcid.org/0000-0002-8466-0916)
- Antoine Lewin (ORCID: https://orcid.org/0000-0003-1748-4198)
- Hans L. Zaaijer (ORCID: https://orcid.org/0000-0003-0773-7315)
- Sylvie Lachance
Institutions
- Héma-Québec (CA)
- Animal and Plant Health Agency (GB)
- Sanquin (NL)
- Canadian Blood Services (CA)
Publication Details
- Journal
- Transfusion
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1111/trf.18381
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00